Actelion must face US antitrust suit over delayed generic version of Tracleer
MLex Summary: A US judge has denied defendants Actelion Pharmaceuticals and Janssen Research & Development's motion for summary judgement over government employees' allegations it blocked market entry for the generic version...To view the full article, register now.
Already a subscriber? Click here to view full article